Intravenous dexmedetomidine as addition to dexamethasone for interscalene brachial plexus block for postoperative analgesia after arthroscopic shoulder surgery: A randomised, double-blinded, single centre trial.
Hervé Vanden Eede, Sophie Noels, Marco Vreven, Jo Dujardyn, Martin Vanden Eede, Jordi Branders, Lise Vanden Eede, Gilles De Herdt, Isabelle Noels, Jason Bouziotis, Vera Saldien
{"title":"Intravenous dexmedetomidine as addition to dexamethasone for interscalene brachial plexus block for postoperative analgesia after arthroscopic shoulder surgery: A randomised, double-blinded, single centre trial.","authors":"Hervé Vanden Eede, Sophie Noels, Marco Vreven, Jo Dujardyn, Martin Vanden Eede, Jordi Branders, Lise Vanden Eede, Gilles De Herdt, Isabelle Noels, Jason Bouziotis, Vera Saldien","doi":"10.1097/EJA.0000000000002196","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The co-administration of intravenous dexamethasone and dexmedetomidine is reported to prolong the duration of analgesia after single-shot interscalene brachial plexus block. The most effective dose with minimal side effects remains undetermined.</p><p><strong>Objectives: </strong>To evaluate the difference in time to first analgesic request in patients receiving different doses of intravenous dexmedetomidine after an interscalene brachial plexus block undergoing arthroscopic shoulder surgery.</p><p><strong>Design: </strong>A double-blind, randomised controlled study.</p><p><strong>Setting: </strong>A single-centre study from November 2021 to December 2023.</p><p><strong>Patients: </strong>Two hundred and eighteen patients undergoing arthroscopic shoulder surgery were included.</p><p><strong>Interventions: </strong>Patients were randomly assigned to one of four groups using blocked randomisation: intravenous 0.9% saline (group 1) or intravenous dexmedetomidine: 1.0 (group 2), 1.5 (group 3) and 2.0 (group 4) μg kg -1 .</p><p><strong>Main outcome measures: </strong>The primary outcome was the time to first analgesic request in hours.</p><p><strong>Results: </strong>There was no significant difference in the time to first analgesic request: group 1 (18.8 ± 6.3 h), group 2 (18.7 ± 5.1 h), group 3 (17.7 ± 5.6 h) and group 4 (19.5 ± 5.0 h). There was no significant difference in postoperative nausea and vomiting, patient satisfaction and quality of sleep in the first 24 h. There were significant differences in the incidences of intra-operative hypotension and bradycardia between the control group and all the dexmedetomidine groups combined; however, this study was not powered for this analysis. The time to extubation was statistically significantly higher in group 4 with a prolonged time to extubation (>14 min) when the duration of surgery was shorter (OR 0.98, 95% CI 0.96 to 0.99).</p><p><strong>Conclusions: </strong>Administering high doses of intravenous dexmedetomidine may not yield additional analgesic benefits after single-shot interscalene brachial plexus block while potentially increasing haemodynamic risks and prolonging time to extubation.</p><p><strong>Trial registration: </strong>EudraCT 2021-004686-12.</p>","PeriodicalId":11920,"journal":{"name":"European Journal of Anaesthesiology","volume":" ","pages":"808-816"},"PeriodicalIF":6.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Anaesthesiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/EJA.0000000000002196","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The co-administration of intravenous dexamethasone and dexmedetomidine is reported to prolong the duration of analgesia after single-shot interscalene brachial plexus block. The most effective dose with minimal side effects remains undetermined.
Objectives: To evaluate the difference in time to first analgesic request in patients receiving different doses of intravenous dexmedetomidine after an interscalene brachial plexus block undergoing arthroscopic shoulder surgery.
Design: A double-blind, randomised controlled study.
Setting: A single-centre study from November 2021 to December 2023.
Patients: Two hundred and eighteen patients undergoing arthroscopic shoulder surgery were included.
Interventions: Patients were randomly assigned to one of four groups using blocked randomisation: intravenous 0.9% saline (group 1) or intravenous dexmedetomidine: 1.0 (group 2), 1.5 (group 3) and 2.0 (group 4) μg kg -1 .
Main outcome measures: The primary outcome was the time to first analgesic request in hours.
Results: There was no significant difference in the time to first analgesic request: group 1 (18.8 ± 6.3 h), group 2 (18.7 ± 5.1 h), group 3 (17.7 ± 5.6 h) and group 4 (19.5 ± 5.0 h). There was no significant difference in postoperative nausea and vomiting, patient satisfaction and quality of sleep in the first 24 h. There were significant differences in the incidences of intra-operative hypotension and bradycardia between the control group and all the dexmedetomidine groups combined; however, this study was not powered for this analysis. The time to extubation was statistically significantly higher in group 4 with a prolonged time to extubation (>14 min) when the duration of surgery was shorter (OR 0.98, 95% CI 0.96 to 0.99).
Conclusions: Administering high doses of intravenous dexmedetomidine may not yield additional analgesic benefits after single-shot interscalene brachial plexus block while potentially increasing haemodynamic risks and prolonging time to extubation.
期刊介绍：
The European Journal of Anaesthesiology (EJA) publishes original work of high scientific quality in the field of anaesthesiology, pain, emergency medicine and intensive care. Preference is given to experimental work or clinical observation in man, and to laboratory work of clinical relevance. The journal also publishes commissioned reviews by an authority, editorials, invited commentaries, special articles, pro and con debates, and short reports (correspondences, case reports, short reports of clinical studies).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
